The higher prevalence of advanced CKD and albuminuria among the subjects with FGF-21 ≥1.40 pg/dl suggested that they were at a high risk of the progression of DKD, and the more extensive coverage of RAS blockade suggested that they were at a more intensive therapy for preventing the deterioration of renal functions. This evidence concerns the gene FGF21 and chronic kidney disease.